← Back to Clinical Trials
Recruiting Phase 1 NCT05683184

OMAR Opioid Use Disorder

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Healthy Control
Sponsor Yale University
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 30
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-03-10
Completion 2026-12-15
Interventions
[11C]OMAR

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.

Eligibility Criteria

Inclusion Criteria: * Able to provide informed consent * Male and female 18 years and older * DSM-5 diagnosis of opioid use disorder (for OUD group) * Physically healthy i.e., no clinically unstable medical conditions * Written informed consent and have capacity to consent and comply with study procedures Exclusion Criteria: * Current neuro-psychiatric illness or severe systemic disease (opioid use disorder is permitted in the OUD group). * Presence of ferromagnetic metal in the body or heart pacemaker * Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits * Are claustrophobic

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE HEALTHY CONTROL TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}